Immunovant, Inc. IMVT
We take great care to ensure that the data presented and summarized in this overview for Immunovant, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMVT
View all-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.88MShares$189 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.52% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.34MShares$91.8 Million0.21% of portfolio
-
State Street Corp Boston, MA2.83MShares$77.9 Million0.0% of portfolio
-
Alpine Global Management, LLC New York, NY2.63MShares$72.3 Million25.81% of portfolio
-
Morgan Stanley New York, NY2.31MShares$63.5 Million0.0% of portfolio
Latest Institutional Activity in IMVT
Top Purchases
Top Sells
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Transactions at IMVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 23
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,385
-1.06%
|
$42,930
$18.15 P/Share
|
|
Jul 23
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,805
-1.35%
|
$50,490
$18.15 P/Share
|
|
Jul 09
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,160
-0.51%
|
$19,720
$17.24 P/Share
|
|
Jul 09
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,519
-0.73%
|
$25,823
$17.24 P/Share
|
|
May 01
2025
|
Robert Graham Susman |
BUY
Grant, award, or other acquisition
|
Direct |
25,016
+50.0%
|
-
|
|
May 01
2025
|
Jake Bauer |
BUY
Grant, award, or other acquisition
|
Direct |
25,016
+50.0%
|
-
|
|
May 01
2025
|
Tiago Girao Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
208,388
+50.0%
|
-
|
|
Apr 23
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,349
-1.03%
|
$32,886
$14.79 P/Share
|
|
Apr 23
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,925
-0.91%
|
$26,950
$14.79 P/Share
|
|
Apr 16
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,321
-0.7%
|
$116,494
$14.89 P/Share
|
|
Apr 16
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,993
-0.75%
|
$41,902
$14.89 P/Share
|
|
Apr 09
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,094
-2.31%
|
$337,128
$12.99 P/Share
|
|
Apr 01
2025
|
Christopher Van Tuyl Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,787
+24.01%
|
-
|
|
Apr 01
2025
|
Michael Geffner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,574
+30.28%
|
-
|
|
Apr 01
2025
|
Jay S Stout Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,181
+26.06%
|
-
|
|
Apr 01
2025
|
Melanie Gloria Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,181
+29.04%
|
-
|
|
Apr 01
2025
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
265,820
+17.96%
|
-
|
|
Apr 01
2025
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,878
+17.79%
|
-
|
|
Apr 01
2025
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,188
+10.55%
|
-
|
|
Apr 01
2025
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,188
+13.02%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.4M shares |
|---|---|
| Open market or private purchase | 16.8M shares |
| Open market or private sale | 187K shares |
|---|